Filing Flows › Health Care › Volitionrx (VNRX)
Volitionrx (VNRX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Volitionrx (VNRX) Q2 2026 earnings results →
Q2 2026 Revenue down 2% year over year to $399K
Volitionrx made $399K in Q2 2026 (-2% Y/Y). Operating margin n/m, net loss $7.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $399K in Q2 2026, down 2% year over year and down 60% from the previous quarter.
Operating costs exceeded revenue by $4.2M, an operating margin of -1042.5%. Total costs fell 32% while revenue fell 2%. The quarter ended with a net loss of $7.3M, wider than the previous quarter's $6.7M loss.
Operating cash flow was −$5.2M. Non-cash charges added back $188K of depreciation and amortization and $238K of share-based compensation. Working capital and other items added $1.7M. Capital expenditures of $2K exceeded it, leaving free cash flow of −$5.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $399K | -2% | n/m | −$7.3M | −$5.2M |
| Q1 2026 | 10-Q | May 14, 2026 | $985K | +300% | -543.0% | −$6.7M | −$5.3M |
| Q4 2025 | 10-K | Mar 31, 2026 | $447K | +133% | n/m | −$6.3M | −$5.5M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $627K | +32% | -813.2% | −$5.4M | −$3.6M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $407K | +3% | n/m | −$6.3M | −$6.3M |
| Q1 2025 | 10-Q | May 15, 2025 | $246K | +44% | n/m | −$5.5M | −$4.3M |
| Q4 2024 | 10-K | Mar 31, 2025 | $192K | -21% | n/m | −$5.9M | −$5.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Volitionrx
Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests. Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors as biomarkers in cancer and other diseases. The tests in the Company’s product portfolio detect certain characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a better way to monitor disease progression and a patient’s response to treatment.
In its own words, from its 10-K, filed Mar 31, 2026.
Volitionrx against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -2% against the peers' median +2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VNRX Volitionrx | Q2 2026 | $399K | -2% | n/m |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
Source: Volitionrx 10-Q on SEC EDGAR · CIK 93314 · In Vitro & In Vivo Diagnostic Substances
13F: who owns VNRX and who is buying
More on VNRX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results